Airline stocks, Boeing tumble as Covid cases climb

Health, Fitness & Food

Passengers board an American Airlines flight at Ronald Reagan Washington National Airport in Arlington, Virginia on April 11, 2021.
Andrew Caballero-Reynolds | AFP | Getty Images

U.S. airline stocks tumbled in early trading Monday as an uptick in Covid-19 cases raised concerns about the economic recovery and hitting one of the sectors most closely tied to loosened pandemic restrictions especially hard.

American Airlines and United Airlines were each down more than 6% in morning trading on Monday. Delta Air Lines was down more than 5% and Southwest Airlines was off close to 5%. Hotel chains Hilton and Marriott were off more than 3% and 4%, respectively.

Travel demand has surged since the spring and airlines Delta and American last week issued upbeat outlooks thanks to a jump bookings. The Transportation Security Administration screened nearly 2.23 million people at U.S. airports on Sunday, the most since Feb. 28, 2020, weeks before the World Health Organization declared Covid-19 a pandemic.

But concerns over the fast-spreading delta variant of Covid, now the dominant strain in the U.S., weighed on the market broadly Monday. Travel stocks that are sensitive to case counts and accompanying restrictions fell more than other sectors.

Some pandemic rules are returning due to the increase in cases. Los Angeles County reinstated an indoor mask mandate last week, even for people who are vaccinated, due to an increase in Covid-19 cases there. The Southern Nevada Health District, which covers Las Vegas, is also urging everyone to wear masks indoors as cases rise across the state.

Cases in the U.S. have jumped by about 66% in the past week to a seven-day average of about 32,300 new cases per day, according to a CNBC analysis of data compiled by Johns Hopkins University.

Products You May Like

Articles You May Like

FDA Approves Anifrolumab (Saphnelo) as New Lupus Treatment
Flexible work has women more optimistic about the future
CHOP researchers identify two proteins that could be used for a potential NTHi vaccine
FDA Grants Priority Review for Levo Therapeutics’ New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
U.S. FDA Accepts Filing of Hutchmed’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Leave a Reply

Your email address will not be published. Required fields are marked *